Prelude Therapeutics (PRLD) FCF Margin (2024 - 2026)

Prelude Therapeutics has reported FCF Margin for 3 years, with the latest figure at 473.47% in Q1 2026.

• Quarterly FCF Margin changed N/A year-over-year to 473.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 261.82% (changed N/A YoY) and the FY2025 annual result came in at 464.32%, up 100565.0% from the prior year.
• FCF Margin eased to 473.47% in Q1 2026 per PRLD's latest filing, from 409.91% in the prior quarter.
• Over five years, FCF Margin peaked at 409.91% in Q4 2025 and troughed at 911.97% in Q3 2024.
• A 3-year average of 354.14% and a median of 473.47% in 2026 frame the typical range for FCF Margin.
• The widest YoY moves for FCF Margin: up 91099 bps in 2025, down 61789 bps in 2025.
• Over 3 years, FCF Margin stood at 501.08% in 2024, then soared by 182 bps to 409.91% in 2025, then plunged by 216 bps to 473.47% in 2026.
• According to Business Quant data, FCF Margin over the past three periods registered 473.47%, 409.91%, and 294.08% for Q1 2026, Q4 2025, and Q3 2025 respectively.